KMT2A and acute lymphoblastic leukemia: Taken together, this underlies the potential of a CD133-targeted therapy, particularly in MLL-AF4 ALL, which accounts for 5–10% of all B-ALL patients that have a particularly poor prognosis [23,37,38].